Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visceral fat area changes and islet β-cell function in type 2 diabetes mellitus
ChiCTR2200066069Phase 4Not yet recruiting
- Sponsor
- Luohu District People's Hospital
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin, semaglutide and dapagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Luohu District People's Hospital. Primary endpoints: Visceral fat area, Fasting plasma glucose and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200066069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066069.